Home » Stocks » JNCE

Jounce Therapeutics, Inc. (JNCE)

Stock Price: $8.57 USD -0.52 (-5.72%)
Updated Apr 19, 2021 11:22 AM EDT - Market open
Market Cap 464.90M
Revenue (ttm) 62.34M
Net Income (ttm) -43.84M
Shares Out 35.43M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE 21.14
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $8.57
Previous Close $9.09
Change ($) -0.52
Change (%) -5.72%
Day's Open 8.97
Day's Range 8.52 - 9.26
Day's Volume 76,309
52-Week Range 4.30 - 14.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

1 week ago - GlobeNewsWire

-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature-

1 week ago - GlobeNewsWire

With the trading day nearing halfway over, the broad markets were trading sideways on Monday.

Other stocks mentioned: COP, PSTG, SIG, AXTA, DOW, ONEM, TXG ...
1 month ago - 24/7 Wall Street

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

1 month ago - GlobeNewsWire

- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 -

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

2 months ago - GlobeNewsWire

Time will always be on the investor's side.

Other stocks mentioned: CORT, CRSP, FATE, LXRX
2 months ago - The Motley Fool

These baby biotechs are itching to come out of their shells.

Other stocks mentioned: SURF
3 months ago - The Motley Fool

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

3 months ago - GlobeNewsWire

Jounce is developing several novel immunotherapies that target T cells and macrophages. I am bearish on the success of Vopratelimab and JTX-8064 and neutral on the prospects of JTX-4014 and JTX-1811.

3 months ago - Seeking Alpha

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

4 months ago - GlobeNewsWire

-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce's PD-1 inhibitor, JTX-4014 -

5 months ago - GlobeNewsWire

- Preclinical data highlight Jounce's approach to identif y potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064 -

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

5 months ago - GlobeNewsWire

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020-

5 months ago - GlobeNewsWire

The company announced disappointing news from a phase 2 study.

5 months ago - The Motley Fool

CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

5 months ago - GlobeNewsWire

These biotechs have a long road ahead, but they just might deliver massive growth.

Other stocks mentioned: RUBY, SRNE
6 months ago - The Motley Fool

Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash

7 months ago - Seeking Alpha

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pre...

7 months ago - GlobeNewsWire

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Other stocks mentioned: GILD
7 months ago - Zacks Investment Research

Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc.

Other stocks mentioned: GILD
7 months ago - 24/7 Wall Street

Shares of Gilead Sciences Inc. GILD, +2.28% were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.

Other stocks mentioned: GILD
7 months ago - Market Watch

  – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody –

7 months ago - GlobeNewsWire

Jounce Therapeutics' (JNCE) CEO Rich Murray on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

8 months ago - GlobeNewsWire

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

10 months ago - GlobeNewsWire

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, MRSN, STRO
10 months ago - The Motley Fool

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

10 months ago - GlobeNewsWire

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

1 year ago - Zacks Investment Research

Jounce Therapeutics: An Attractive Immunotherapy Pick For 2020

1 year ago - Seeking Alpha

Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System

1 year ago - Seeking Alpha

CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

1 year ago - GlobeNewsWire

Is (JNCE) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.

Other stocks mentioned: AEGN, FBM, ICHR, SPAR
1 year ago - Zacks Investment Research

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.

Other stocks mentioned: FBM, FRTA, HIBB, OESX
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).

1 year ago - Zacks Investment Research

About JNCE

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expr... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2017
CEO
Richard Murray
Employees
128
Stock Exchange
NASDAQ
Ticker Symbol
JNCE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 16.00, which is an increase of 86.70% from the latest price.

Price Target
$16.00
(86.70% upside)
Analyst Consensus: Buy